Results 51 to 60 of about 4,050,496 (258)

WHO HAS THERAPY-RELATED AML?

Mediterranean Journal of Hematology and Infectious Diseases, 2017
Therapy-related leukemia or therapy-related myeloid neoplasm are widely-used terms to designate leukemia developing in persons who previously received anti-cancer therapy (for example, see references 1, 2), especially if the prior anti-cancer therapy ...
Robert Gale, John M. Bennett, F. Owen Hoffman   +2 more
doaj   +1 more source

Functions of the CSB Protein at Topoisomerase 2 Inhibitors-Induced DNA Lesions

Frontiers in Cell and Developmental Biology, 2021
Topoisomerase 2 (TOP2) inhibitors are drugs widely used in the treatment of different types of cancer. Processing of their induced-lesions create double-strand breaks (DSBs) in the DNA, which is the main toxic mechanism of topoisomerase inhibitors to ...
Franciele Faccio Busatto, Franciele Faccio Busatto, Franciele Faccio Busatto, Franciele Faccio Busatto, Sofiane Y. Mersaoui, Sofiane Y. Mersaoui, Yilun Sun, Yves Pommier, Jean-Yves Masson, Jean-Yves Masson, Jenifer Saffi, Jenifer Saffi   +11 more
doaj   +1 more source

The impact of the human DNA topoisomerase II C-terminal domain on activity [PDF]

, 2008
Background Type II DNA topoisomerases (topos) are essential enzymes needed for the resolution of topological problems that occur during DNA metabolic processes.
West, K.L., Katherine L West, Meczes, E.L., Kathryn L Gilroy, Caroline A Austin, Austin Caroline A., Austin, C.A., Gilroy Kathryn L., Meczes Emma L., Gilroy, K.L., Emma L Meczes, West Katherine L.   +11 more
core   +2 more sources

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Science Translational Medicine, 2020
Triple-negative breast cancer xenografts with BRCAness, high expression of SLFN11, and RB1 loss are highly sensitive to topoisomerase I inhibitors. Starting at the TOP for cancer treatment Topoisomerase (TOP) inhibitors are chemotherapeutic drugs that ...
F. Coussy, R. El-Botty, S. Chateau-Joubert, A. Dahmani, E. Montaudon, S. Leboucher, L. Morisset, P. Painsec, L. Sourd, L. Huguet, F. Némati, J. Servely, T. Larcher, S. Vacher, A. Briaux, C. Reyes, P. La Rosa, Georges Lucotte, T. Popova, P. Foidart, N. Sounni, A. Noel, D. Decaudin, L. Fuhrmann, A. Salomon, F. Reyal, C. Mueller, Petra ter Brugge, J. Jonkers, M. Poupon, M. Stern, I. Bièche, Y. Pommier, E. Marangoni   +33 more
semanticscholar   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Benzothiazole derivatives as human DNA topoisomerase II alpha inhibitors [PDF]

, 2013
Benzothiazole derivatives resembling the structure of DNA purine bases were tested to determine their topoisomerase inhibition activities. Based on DNA topoisomerase I and II relaxation assay results, all 12 derivatives acted as human topoisomerase II ...
Aki, Esin, DİRİL, NURAN, Yalcin, Ismail, Tekiner-Gulbas, Betul, YILDIZ, İLKAY, Kaplan-Ozen, Cigdem, Foto, Egemen   +6 more
core   +2 more sources

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Dual inhibitors of human DNA topoisomerase II and other cancer-related targets.

Journal of Medicinal Chemistry, 2020
Human DNA topoisomerase II is an important target in anticancer therapy. Despite the clinical success of drugs that target topoisomerase II, the development of resistant cancer cells can limit their clinical efficacy.
Ž. Skok, Nace Zidar, D. Kikelj, J. Ilaš   +3 more
semanticscholar   +1 more source

The Difficult Case of Crystallization and Structure Solution for the ParC55 Breakage-Reunion Domain of Topoisomerase IV from Streptococcus pneumoniae. [PDF]

, 2008
BACKGROUND: Streptococcus pneumoniae is the major cause of community-acquired pneumonia and is also associated with bronchitis, meningitis, otitis and sinusitis.
Laponogov, I, Pan, Xiao-Su, L Mark Fisher, Veselkov, DA, Sanderson, MR, Xiao-Su Pan, Sohi, MK, Mark R Sanderson, Fisher, L. Mark, Sanderson, Mark R., Laponogov, Ivan, Fisher, LM, Dennis A Veselkov, Pan, XS, Maninder K Sohi, Veselkov, Dennis A., Ivan Laponogov, Sohi, Maninder K.   +17 more
core   +1 more source